» Download Public Reports
About 100 reports
- Country report
- April 2013
- 21 pages
... Industrial health sectors chemical and biotech industries medicines active principles vaccines hemoderivatives biologics diagnostic reagents mechanic, electronic and material industries hospitals out ...
October 2012
... In q3 11) - Operational revenues excluding ascent operations grew by 16% to rs.213 Crores (rs.185 Crores in q3 11) With ebitda margin at 14% - retained vancomycin oral market share of over 30 ...
February 2013
... As compared to a control treatment. In addi- tion, when fish were challenged with viru- lent viral and bacterial strains, the survival of orally vaccinated fish was significantly higher than ...
October 2012
... In this quarter if you look at the total covered market that growth is still good it is around 26% or so but the growth in the covered market is driven by two molecules losartan and metformin, which ...
May 2012
... Deficit We achieved almost all of the development goals of the millenium before 2015. Almost 40 million brazilians raised up from poverty to middle class Brazil stands for access to medicines ...
May 2012
... Of the national drugs observatories. 3. Capacity-building on demand reduction. 4. Capacity-building on supply reduction. The programme has been running since january 2011 and has been fully operational now ...
July 2012
... For slds qa and management can be described as a rationally established environment Where the state is a key actor from drugs production & procurement to rational use, with efficient systems ...
January 2013
... Development and production of influenza vaccines instituto butantan prof. Isaias raw january 2013 butantan: goals As a public institute, the goal of butantan is to produce efficacious ...
January 2013
... Fully-automated molecular test. Simultaneously detects tb and rifampin drug resistance Provides accurate results in less than two hours so that patients can be oered proper treatment ...
» Purchase Premium Reports
(From $ 250 - $ 2 000)
About 100 reports
- $ 2 000
- Industry report
- February 2013
- by Global Markets Direct
Encephalitis - Pipeline Review, H1 2013 Summary Global Markets Direct's, 'Encephalitis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides ...
May 2013
$ 1 088
Includes 3 FREE quarterly updates BMI View: The attractiveness of Argentina's pharmaceutical industry to drug industry players is deteriorating due to the country's unsustainable macroeconomic trajectory ...
May 2013
$ 1 088
Includes 3 FREE quarterly updates BMI View: Chile's pharmaceutical industry is expected to become an increasingly attractive proposition for multinational industry players as regulatory and intellectual ...
April 2013
$ 1 088
BMI View: Peru's large and growing population underpins the potential of its pharmaceutical industry , especially given the rising prevalence of non-communicable diseases. However, Peru remains listed ...
April 2013
$ 1 088
BMI View: Measured in local currency and in US dollars, the value of Argentina's pharmaceutical industry is expected to grow at double-digit rates over the five years to 2016, in large part due to inflationary ...
April 2013
$ 1 088
Includes 3 FREE quarterly updates BMI View: Venezuela's pharmaceutical market will face increasingly harsh pricing policy which is unlikely to tackle the persistent medicine shortage problem. President ...
March 2013
$ 1 088
Includes 3 FREE quarterly updates BMI View: Brazil remains the most attractive emerging pharmaceutical industry in the Americas due to its large population, strong consumer demand, increasing urbanisation ...
